NCCN molecular testing white paper: Effectiveness, efficiency, and reimbursement Review uri icon


MeSH Major

  • Medical Oncology
  • Molecular Biology
  • Neoplasms


  • Personalized medicine in oncology is maturing and evolving rapidly, and the use of molecular biomarkers in clinical decision-making is growing. This raises important issues regarding the safe, effective, and efficient deployment of molecular tests to guide appropriate care, specifically regarding laboratory-developed tests and companion diagnostics. In May 2011, NCCN assembled a work group composed of thought leaders from NCCN Member Institutions and other organizations to identify challenges and provide guidance regarding molecular testing in oncology and its corresponding utility from clinical, scientific, and coverage policy standpoints. The NCCN Molecular Testing Work Group identified challenges surrounding molecular testing, including health care provider knowledge, determining clinical utility, coding and billing for molecular tests, maintaining clinical and analytic validity of molecular tests, efficient use of specimens, and building clinical evidence.

publication date

  • December 2011



  • Review



  • eng

PubMed ID

  • 22203777

Additional Document Info

start page

  • S1

end page

  • 16


  • 9


  • SUPPL.6